Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Did anyone

<< Previous

Bullboard Posts

Next >>

Comment by Whyme16on Apr 14, 2020 3:09pm

105 Views

Post# 30908586

RE:Did anyone

I have e-mailed them several times with my questions. NOONE ever replied to any of my question!!

bud13 (244)

44 minutes ago

35 Reads

Post# 30908332

Did anyone

get intouch with our ceo to find out what's going on here. Something don't add up. Hopefully it's in the wash and going to be clean when it comes off the line

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market